21288-61-9

Usage

Uses

Used in Pharmaceutical Industry:
Epsilon-pyrromycinone is used as a potential anticancer agent for its demonstrated efficacy in inhibiting the growth of various cancer cell lines, such as lung cancer, breast cancer, and leukemia. Its mechanism of action involves inducing apoptosis and disrupting DNA replication and repair processes in cancer cells, making it a promising candidate for the development of novel anticancer therapies.
Used in Cancer Research:
Epsilon-pyrromycinone is utilized in preclinical studies and ongoing research to further explore its anticancer properties and potential applications in cancer treatment. Its unique mechanism of action and cytotoxic effects on cancer cells provide valuable insights for the development of new therapeutic strategies and drug candidates in the fight against cancer.

InChI:InChI=1/C22H20O9/c1-3-22(30)7-12(25)13-8(17(22)21(29)31-2)6-9-14(19(13)27)20(28)16-11(24)5-4-10(23)15(16)18(9)26/h4-6,12,17,23-25,27,30H,3,7H2,1-2H3/t12-,17-,22+/m0/s1

Upstream product

• 124222-85-1 pyrromycin; hydrochloride 
• 16234-96-1 (+)-aklavinone 
• 88453-75-2 methyl <3-(3-(benzyloxy)pent-1-yl)-4,5,8-trimethoxyanthraquinon-2-yl>acetate 
• 88453-81-0 10(R,S)-(methoxycarbonyl)-9(R,S)-ethyl-9(R,S)-hydroxy-7,8,9,10-tetrahydro-1,4,6-trimethoxy-5,12-naphthacenedione 
• 88453-73-0 methyl 2-<3-(3-(benzyloxy)pent-1-yl)-5,8-dimethoxy-4-hydroxyanthraquinon-2-yl>acetate 
• 88453-78-5 methyl <3-(3-oxopent-1-yl)-4,5,8-trimethoxyanthraquinon-2-yl>acetate 
• 88453-76-3 methyl <3-(3-hydroxypent-1-yl)-4,5,8-trimethoxyanthraquinon-2-yl>acetate 
• 641-92-9 (+/-)-ε-deoxypyrromycinone 

Downstream Products

• 129985-41-7 7-O-<4-O-<4-O-(2,3,6-trideoxy-α-L-glycero-hexopyranosid-4-ulosyl)-2,6-dideoxy-3-O-(trimethylsilyl)-α-L-lyxo-hexopyranosyl>-2,6-dideoxy-2-iodo-3-O-(trimethylsilyl)-α-L-talopyranosyl>-ε-pyrromycinone 
• 129985-41-7 7-O-<4-O-<4-O-(2,3,6-trideoxy-α-L-glycero-hexopyranosid-4-ulosyl)-2,6-dideoxy-3-O-(trimethylsilyl)-α-L-lyxo-hexopyranosyl>-2,6-dideoxy-2-iodo-3-O-(trimethylsilyl)-α-L-galactopyranosyl>-ε-pyrromycinone 
• 129985-41-7 7-O-<4-O-<4-O-(2,3,6-trideoxy-α-L-glycero-hexopyranosid-4-ulosyl)-2,6-dideoxy-3-O-(trimethylsilyl)-α-L-lyxo-hexopyranosyl>-2,6-dideoxy-2-iodo-3-O-(trimethylsilyl)-β-L-galactopyranosyl>-ε-pyrromycinone 
• 76069-70-0 daunosaminyl ε-pyrromycinone 
• 749-18-8 1-hydroxybisanhydroaklavinone 
• 111233-40-0 ciclamycin 0 
• 167012-88-6 7-O-<(2,3,6-trideoxy-4-ulo-α-L-hexopyranosyl)-(1->4)-<2,6-dideoxy-3-O-(4-methoxybenzyl)-α-L-galactopyranosyl>-(1->4)-2,6-dideoxy-3-O-(4-methoxybenzyl)-1-(2,6-dichlorophenylsulfinyl)-α-L-galactopyranosyl>-ε-pyrromycinone 

Relevant academic research and scientific papers

Directed Biosynthesis of Iso-aclacinomycins with Improved Anticancer Activity

A four-enzyme catalyzed hydroxy regioisomerization of anthracycline was integrated into the biosynthetic pathway of aclacinomycin A (ALM-A), to generate a series of iso-ALMs via directed combinatorial biosynthesis combined with precursor-directed mutasynthesis. Most of the newly acquired iso-ALMs exhibit obviously (1-5-fold) improved antitumor activity. Therefore, we not only developed iso-ALMs with potential as clinical drugs but also demonstrated the utility of this tailoring tool for modification of anthracycline antibiotics in drug discovery and development.

Regiospecific Total Syntheses of (+/-)-Aklavinone and (+/-)-ε-Pyrromycinone from a Common Synthon

The preparation and use of cyclohexenone 10 as a common intermediate for regiospecific total synthesis of both (+/-)-aklavinone (1a) and (+/-)-ε-pyrromycinone (2a) is described.